# Franklin Crypto Trust: financial statements, quarterly

EZPZ · CBOE · CIK 2033807 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ezpz.md) · [Financials](/companies/ezpz/financials.md) · [Filings](/companies/ezpz/filings.md) · [Insiders](/companies/ezpz/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ezpz/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Income tax | $k | [0.0](/filings/0001140361-25-018908.md) | not reported | not reported | [0.0](/filings/0001140361-26-020861.md) | [0.0 d](/filings/0001140361-26-033200.md) |
| Net income | $k | not reported | [974](/filings/0001140361-26-033200.md) | [459](/filings/0001140361-25-041940.md) | [(2,464)](/filings/0001140361-26-020861.md) | [(1,704)](/filings/0001140361-26-033200.md) |

- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss

## Balance sheet

| Line item | Unit | period not labelled (2025-02-19) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total assets | $m | not reported | [3.1](/filings/0001140361-25-018908.md) | [4.1](/filings/0001140361-25-030871.md) | [7.6](/filings/0001140361-25-041940.md) | [10.2](/filings/0001140361-26-033200.md) | [10.4](/filings/0001140361-26-020861.md) | [11.7](/filings/0001140361-26-033200.md) |
| Total liabilities | $m | not reported | [0.0](/filings/0001140361-25-018908.md) | [0.0](/filings/0001140361-25-030871.md) | [0.0](/filings/0001140361-25-041940.md) | [0.0](/filings/0001140361-26-033200.md) | [0.0](/filings/0001140361-26-020861.md) | [0.0](/filings/0001140361-26-033200.md) |
| Shareholders' equity | $m | [2.5](/filings/0001140361-26-033200.md) | [3.5](/filings/0001140361-26-033200.md) | [3.5](/filings/0001140361-26-033200.md) | [6.5](/filings/0001140361-25-041940.md) | [11.7](/filings/0001140361-26-033200.md) | [14.4](/filings/0001140361-26-033200.md) | [17.4](/filings/0001140361-26-033200.md) |

- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: |
| Operating cash flow | $k | [(2,629)](/filings/0001140361-26-020861.md) | [(3,057) d](/filings/0001140361-26-033200.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

Shares outstanding: 900,000 at 2026-08-03, from the cover of the [10-Q filed 2026-08-14](/filings/0001140361-26-033200.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.